MSCopilot® digital biomarkers obtained in a real-world setting correlated with their clinical counterparts in the MS-DETECT study

        

We attended the ECTRIMS Congress in Barcelona, Spain, in September 2025 to unveil the results of the MS-DETECT study. The study aims to evaluate the effectiveness of MSCopilot® in detecting disease progression in real life. Our medical device allows users to measure their walking, dexterity, cognitive functions, and visual acuity at home. Its overall score correlates with the MSFC-4 (the Multiple Sclerosis Functional Composite with its 4 Components) and the EDSS (Expanded Disability Status Scale), confirming its potential to detect worsening disability in a way that complements existing tools.

Share